Novartis AG's Experimental Skin Cancer Drug Meets Primary Endpoint In Pivotal Phase 2 Trial

Novartis investigational compound LDE225 met primary endpoint in pivotal trial for patients with advanced basal cell carcinoma Basel, February 19, 2014 - Novartis announced today that the pivotal trial of the investigational oral compound LDE225 in advanced basal cell carcinoma met its primary endpoint of demonstrating an objective response rate ... (more)

http://ift.tt/1ctWR2F